• Nirui Shen, Qingting Wang, Yuanjie Qiu, Yan Wang, Danyang Li, and Manxiang Li.
• Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
• Medicine (Baltimore). 2022 Jul 1; 101 (26): e29806e29806.

BackgroundRegulator of cullins 1 (ROC1) is frequently overexpressed in multiple tumors, and many pieces of research demonstrate that ROC1 is associated with the prognosis and development of a diversity of neoplasms and it is able to serve as a promising prognostic biomarker. Here we performed this meta-analysis to evaluate the prognostic and clinicopathological significance of ROC1 in patients suffering from cancer.MethodsWe searched Pubmed, Embase, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and WanFang database. The role of ROC1 in cancers was evaluated by pooled hazard ratios (HRs), odd ratios (ORs) and 95% confidence intervals (CIs).ResultsIn total, 9 studies including 1002 patients were enrolled in this analysis. The pooled results showed that patients with high expression of ROC1 had poor overall survival (OS) (HR: 2.04, 95% CI: 1.48-2.60, P < 0.001) and recurrence-free survival (RFS) (HR: 1.727, 95% CI: 0.965-2.488, P < 0.001). Additionally, elevated expression of ROC1 was significantly correlated with advanced clinical Tumor Node Metastasis stage (OR: 2.708, 95% CI: 1.856-3.951, P < 0.001), positive lymph node metastasis (OR: 1.968; 95% CI: 1.294-2.993, P = .002), large tumor size (OR: 1.522, 95% CI: 1.079-2.149, P = .017) and poor tumor differentiation (OR: 2.448, 95% CI: 1.793-3.344, P < 0.001).ConclusionsElevated ROC1 expression predicted worse prognosis and advanced pathological parameters in various cancers. ROC1 was a significant prognostic biomarker for poor survival in human cancers.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

29 keywords...

hide…